JAMA Oncology : Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
Oct 24, 2024
20:41
Episode Description
Interview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD.
Related Content:
Proudly Supported by
